Cholesteryl ester transfer protein gene and effectiveness of lipid lowering of atorvastatin

Open Cardiovascular Medicine Journal

Volumn 4, Issue , 2010, Pages 297-301

  Kolovou, Genovefa ^a   Mihas, Constantinos ^b   Anagnostopoulou, Katherine ^a   Kolovou, Vana ^a   Giannakopoulou, Vasiliki ^a   Kostakou, Peggy ^a   Stamatelatou, Marianna ^a   Mavrogeni, Sophie ^a   Degiannis, Dimitrios ^a   Mikhailidis, Dimitri P ^c  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b Kimi General Hospital   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atorvastatin; Cholesteryl ester transfer protein; Genetic polymorphisms; Lipid profile

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; CHOLESTEROL ESTER TRANSFER PROTEIN GENE; CONTROLLED STUDY; DNA DETERMINATION; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GREECE; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80051760003     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010297     Document Type: Article

References (26)

1. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006; 111: 893-908.
2. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 2003; 44: 1080-93.
3. Drayna D, Lawn R. Multiple RFLPs at the human cholesteryl ester transfer protein (CETP) locus. Nucleic Acids Res 1987; 15: 4698.
4. Kuivenhoven JA, de Knijff P, Boer JM, et al. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997; 17: 560-8.
5. Szapary PO, Rader DJ. The triglyceride-high-density lipoprotein axis: an important target of therapy? Am Heart J 2004; 148: 211-21.
6. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, et al. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005; 21: 231-44.
7. Kolovou GD, Fostinis YP, Bilianou HI, et al. Response of high-density lipoproteins to hypolipidemic drugs according to their initial level. Am J Cardiol 1995; 75: 293-5.
8. Anagnostopoulou K, Kolovou G, Kostakou P, et al. Pharmacoge-netic study of cholesteryl ester transfer protein gene and simvas-tatin treatment in hypercholesterolaemic subjects. Expert Opin Pharmacother 2007; 8: 2459-63.
9. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
10. Kolovou G, Anagnostopoulou K, Kostakou P, et al. Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia. Clin Chem Lab Med 2007;45: 1190-8.
11. Gudnason V, Kakko S, Nicaud V, et al. Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group. Eur J Clin Invest 1999; 29: 116-28.
12. Hannuksela ML, Liinamaa MJ, Kesäniemi YA, et al. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 1994; 110: 35-44.
13. Freeman DJ, Griffin BA, Holmes AP, et al. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors: associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 1994; 14: 336-44.
14. Hassanzadeh T, Firoozrai M, Zonouz AE, Zavarehee A, Paoli M. Taq1B polymorphism of cholesteryl ester transfer protein (CETP) gene in primary combined hyperlipidaemia. Indian J Med Res 2009;129: 293-8.
15. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338: 86-93.
16. Kolovou GD, Anagnostopoulou KK, Karyofillis P, et al. Choles-teryl ester transfer protein gene polymorphisms and severity of coronary stenosis. Clin Invest Med 2006; 29: 14-9.
17. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006; 119: 676-83.
18. Schmitz G, Drobnik W. Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin Chem Lab Med 2003; 41: 581-9.
19. de Haan W, van der Hoogt CC, Westerterp M, et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden. CETP mice. Atherosclerosis 2008; 197: 57-63.
20. van Venrooij FV, Stolk RP, Banga JD, et al; DALI Study Group. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003; 26: 1216-23.
21. Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK. Common Variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol 2010; 29(10): 629-37. [Epub ahead of print].
22. Mohrschladt MF, van der Sman-de Beer F, Hofman MK, van der Krabben M, Westendorp RG, Smelt AH. TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur J Hum Genet 2005; 13: 877-882.
23. Kolovou GD, Daskalova DC, Petropoulos II, et al. Effect of baseline levels on response of high-density lipoprotein cholesterol to hypolipidemic treatment. Am J Cardiol 2003; 92: 1339-42.
24. Kolovou GD, Cokkinos DV. Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment. Curr Med Res Opin 2002; 18: 265-8.
25. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006; 6: 360-74.
26. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008; 299: 2777-88.